Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma

A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19). One month after the symptoms transiently improved, the patient expe-rienced exacerbated COVID-19 symptoms. The patient recovered from COVID-19 with remdesivir and dex-amethasone and was discharged 77 days after the disease onset. The patient completed a primary series of SARS-CoV-2 vaccinations on day 176, but the anti-spike protein IgG was not detected later. A careful obser-vation to detect any subsequent relapse of COVID-19 symptoms is necessary in immunocompromised pa-tients. Chemotherapy should be based on the disease status and type of lymphoma.

Automated summary

An individual with follicular lymphoma experienced prolonged COVID-19, with exacerbation of symptoms after initial transient improvement. The patient recovered with remdesivir and dexamethasone treatment, but no anti-spike protein IgG was detected after completing a primary series of SARS-CoV-2 vaccinations. Careful observation and appropriate chemotherapy based on disease status and lymphoma type are necessary for immunocompromised patients.